| Literature DB >> 35024728 |
Anca Silvia Dumitriu1, Andreea Cristiana Didilescu, Marina Cristina Giurgiu, Ştefan Dimitrie Albu, Cristiana Elena Pădure, Ximena Anca Nicolae, Stana Păunică.
Abstract
Periodontal disease is an inflammatory condition which affects the covering and support structures of the teeth and, if left untreated, leads to tooth loss. Resorption of the alveolar bone from bi- and trifurcation regions of a multirooted tooth due to the progression of a periodontal disease bears involvement furcation. The degree of furcation involvement is clinically assessed by changes in the vertical and horizontal plane at the root separation area. In the approach of the furcation treatment, the morphological and functional particularities of pluriradicular teeth must be considered and the current techniques look for solutions for the regeneration of the destroyed periodontal tissues. Enamel matrix derivative (EMD) has the role of stimulating healing processes through effects on various growth factors, cement formation, angiogenesis and are used single or in combination with bone graft substitute (BGS) or guided tissue regeneration (GTR) in the complex treatment of periodontal disease. The present study follows PubMed publications on the efficiency of EMD in the treatment of pluriradicular tooth furcations. The findings are that there are not many studies in the usage of EMD associated with the treatment of furcations, but it is an important choice in the complex treatment of destructive periodontal disease, and further studies are needed to be done in periodontal regeneration.Entities:
Mesh:
Year: 2021 PMID: 35024728 PMCID: PMC8848286 DOI: 10.47162/RJME.62.2.06
Source DB: PubMed Journal: Rom J Morphol Embryol ISSN: 1220-0522 Impact factor: 1.033
Figure 1PubMed publications including enamel matrix derivatives (EMDs)
Publications on the use of EMDs in the treatment of periodontal disease molar furcations
|
|
|
|
|
|
|
|
|
1. |
Masaeli |
Review |
|
|
28 articles |
|
|
2. |
Queiroz |
Clinical trial; randomized controlled trial |
EMD; EMD + BGS ( |
3 and 6 months |
41 patients with mandibular class II buccal furcation; 39 samples |
|
|
3. |
Soares |
Systematic review and meta-analysis |
|
|
Five studies qualitative synthesis, two for the quantitative analysis |
|
|
4. |
Ivanovski (2009) [ |
Review |
|
|
|
|
|
5. |
Queiroz |
Clinical trial – case series |
EMD + |
6 months |
13 patients’ class II mandibular furcation (no smokers) |
|
|
6. |
Koop |
Systematic review |
|
|
27 studies for intrabony defects and recession |
One eligible study on furcations follow-up ≥1 year, human studies |
|
7. |
Casarin |
Randomized clinical trial, double-blinded, split-mouth |
OFD + EDTA, OFD + EDTA + EMD |
6, 12 and 24 months |
12 patients presenting bilateral class II proximal furcation, maxillary molars |
|
|
8. |
Queiroz |
Randomized clinical trial, blinded |
EMD, |
12 months |
41 patients, mandibular class II buccal furcation defect |
|
|
9. |
Regazzini |
Dogs, comparative study |
|
|
4 dogs, 3 groups |
|
|
10. |
Meyle |
Randomized clinical trial |
EMD, GTR |
14 months reentry |
48 patients, buccal class II furcation involvements, first and second molars |
Influence of furcation morphology |
|
11. |
Hovey |
Baboons |
|
|
6 female baboons, class III furcation defects |
|
|
12. |
Casarin |
Pearson’s and Spearman’s rank correlation tests |
|
6 months |
18 class II proximal furcations (maxillary molars) |
|
|
13. |
Zhu |
Monkeys |
|
|
3 monkeys, 6 groups, class III furcation defects |
|
|
14. |
Jepsen |
Randomized clinical trial, split-mouth |
EMD, GTR |
14 months reentry |
45 patients with 90 comparable class II mandibular, first and second molars defects |
Antibiotics were prescribed twice after EMD surgery and eight times after membrane surgery |
|
15. |
Fernandes |
Five dogs, histologically and histometrically test-control |
EMD + bioactive glass + GTR, EMD + GTR, bioglass + GTR (control) |
|
20 teeth, 3 groups, one control |
One antibiotic (Penicillin G) i.m. administration |
|
16. |
Palioto |
Dogs, histomorphometrically test-control, 12 weeks |
Four groups |
|
6 dogs |
TGF- |
|
17. |
Peres |
Randomized clinical trial, double-blind |
OFD + |
6 months |
30 patients, proximal class II furcation defects (maxillary molars) |
|
|
18. |
Chitsazi |
Clinical trial, split-mouth |
OFD + EMD, EMD |
6-month reentry |
20 similar bilateral class II furcation defects in 10 patients |
Healthy nonsmoker |
|
19. |
Jaiswal & Deo (2013) [ |
Randomized clinical trial |
EMD + BGS + GTR, BGS + GTR, OFD |
12 months |
30 patients, mandibular class II furcation defects |
Bone allograft, computerized probe, post-surgery: non-steroidal anti-inflammatory medication and systemic antibiotics |
|
20. |
Donos |
Clinical trial case series |
EMD |
6, 12, and 36 months |
10 patients, mandibular degree II furcation |
0.2% Chlorhexidine digluconate three times per day, six weeks postoperative |
|
21. |
Hoffmann |
Randomized clinical trial |
EMD; GTR |
14 months reentry |
48 patients, buccal class II furcation, first and second molars |
Influence of smoking, age, gender, hypertension, and oral hygiene status |
|
22. |
Casarin |
A double-blind randomized clinical trial, randomized controlled trial |
|
2, 4 and 6 months |
15 patients, control group, proximal class II furcation (maxillary molars) |
|
|
23. |
Donos |
Clinical trial |
EMD, GTR, EMD + GTR |
6 and 12 months |
9 patients, class III mandibular furcation |
|
|
24. |
Aimetti |
|
EMD + BGS (autologous) |
24 months |
11 patients, class II furcation defects |
Vital molars with a minimum of 2 mm of keratinized tissue, autologous bone grafts |
|
25. |
Oliveira |
Systematic review and meta-analysis, a minimum follow-up of 12 months |
|
|
19 studies, 618 patients |
|
|
26. |
Sculean |
Review |
|
|
|
|
|
27. |
Trombelli & Farina (2008) [ |
Review |
|
|
|
|
|
28. |
Shirakata |
Monkeys, 16 weeks, histomorphometric analysis |
|
|
3 monkeys, 12 mandibular defects |
|
|
29. |
Mardas |
Comparative study, test-control, dogs, 5 months |
|
|
9 dogs, 17 class III furcation defects |
|
|
30. |
Heard & Mellonig (2000) [ |
Review |
|
|
Maxillary class II furcations |
Excluded |
β-TCP/HA: beta-Tricalcium phosphate/Hydroxyapatite; BGS: Bone graft substitute; DNA: Deoxyribonucleic acid; EDTA: Ethylenediaminetetraacetic acid; EMD: Enamel matrix derivative; GTR: Guided tissue regeneration; i.m.: Intramuscular; OFD: Open flap debridement; TGF-β1: Transforming growth factor-beta 1